🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Check out this retrospective observational study recently published in Oncology and Therapy on #OncotypeDX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive/HER2-Negative Early #BreastCancer 🔓pubmed.ncbi.nlm.nih.gov/40232579/ Stefania Morganti, MD ​​Ann Partridge MD, MPH Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸

Impact of Proton Pump Inhibitors on Osimertinib-Induced Cardiotoxicity in NSCLC Patients link.springer.com/article/10.100… Oncogene Cancer Research

More evidence of the benefit of CDK4/6i in HER2+ MBC seen in a phase 2 study of TD-M1 plus palbociclib. #esmobreast2025 palbociclib benefit was independent of ER status when combined to TD-M1

The #NIMBUS trial results are now published in Nature Communications 👉Nivolumab plus low-dose #ipilimumab in hypermutated HER2-negative #MetastaticBreastCancer. 🔓pubmed.ncbi.nlm.nih.gov/40360544/ ✍️Jorge Gómez Tejeda Zañudo Sangeetha Reddy leisha.emens Carolina Alves Costa Silva, MD, PhD Saud AlDubayan, M.D. د.سعود الدبيان Hoyin Chu Nancy Lin, MD Nabihah Tayob

🔥 Big Win in HR+/HER2– Breast Cancer! Final #INAVO120 results at #ASCO25 show OS benefit with INAVO + PALBO + Fulvestrant in PIK3CA-mutated, endocrine-resistant ABC: ✅ OS: 34.0 vs 27.0 mo ✅ HR 0.67 | p = 0.019 ✅ INV-PFS: 17.2 vs 7.3 mo ✅ ORR: 62.7% vs 28% ✅ TTC delay: ~2

Are you a young oncologist attending #ASCO25? Join us on Monday, June 2 to talk about the Keys to Success for the Early Career Oncologist! 🔑 💫 Check here the sessions scheduled at the Trainee & Early Career Lounge: cdn.bfldr.com/KOIHB2Q3/as/7c… ASCO TECAG ASCO OncoAlert

I’m excited to be representing @danafarber at #ASCO25 to share my findings on onvansertib, an oral Plk1 inhibitor, in combination with paclitaxel in triple-negative MBC. Learn more at poster Bd 79 on Monday morning. Abstract 1100 Dana-Farber’s Breast Oncology Center

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

ASCO primarily focuses on trials exploring new indications for current or emerging therapies, it’s equally compelling to see research aimed at managing adverse effects. interventions for hot flashes offers a valuable reminder of the importance of supportive care in onco

This is data many of who treat the highest risk young patients (N2-3) have waited for for a while! This ahould have been an oral #ASCO2025 Ann Partridge MD, MPH #bcsm

Pleased to share the first series of pts who experienced recurrence on adjuvant abemaciclib+ET: ➤ 9.2% (15/163) recurred ➤ 50% ER loss post-tx ➤ 90% TP53-pathway alterations post-tx ➤ Median 1L m+ tx duration: 3.0 mo (IQR 1.6–5.0) shorturl.at/ZnMI5

Adv HER2+ 🔹DB09: 1L T-DXd + pertuzumab → 40.7m PFS 💥. Open questions: Should ALL pts get it upfront? Induction → maintenance? How do we integrate w/ PATINA (PFS 44m)?

Final results of IMpassion031 by Dr. E Mittendorf et al. published in Nature Medicine. Perioperative atezo, added to chemo, led to more favorable survival outcomes for eTNBC. Most pts cleared ctDNA. Poorest outcomes observed for the few pts with RD & ctDNA+. nature.com/articles/s4159…

Adjuvant Nivolumab in MIUC – Real-World Data with a Focus on Disparities led by Alex Chehrazi-Raffle, MD A quick tweetorial 🧵 ⁉️ Can real-world outcomes of adjuvant nivolumab match those from clinical trials? And how does it perform in underrepresented groups? ➡️We evaluated 253 patients

How to improve outcome in advanced ovarian epithelial cancer post 1st line chemotherapy and sx ? Add IO or parp inhibitors or both or none ? Money slide to summarize all 4 new trials in this space. Taken from #ASCO25 ASCO Kate Sears OncoAlert

What patients are eligible for adjuvant CDK4/6i? We looked at this in ConcertAI: the approval of ribo doubled the pts eligible for adjuvant CDK4/6i (15%➡️30%) and provided an option for 10% of pts with N0 disease, those with the most aggressive cancers. esmoopen.com/article/S2059-…

New study in ESMO Open examines clinicopathological features and genomics of ER-positive/HER2-negative #BreastCancer relapsing on adjuvant #abemaciclib. 🔓pubmed.ncbi.nlm.nih.gov/40466434/ ✍️Chiara Corti Daniel Abravanel, MD/PhD Paolo Tarantino G Curigliano MD PhD Tari King MD Dr. E Mittendorf Nancy Lin, MD Sara Tolaney

Full self-driving in Mexico. I had my doubts, considering the state of some streets, but how wrong was I. This is the next evolution for cars.

Listen to Tunnel by Polo & Pan, Channel Tres tidal.com/browse/track/2…